title: Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned?
authors.affiliation: Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.
authors.forename: Laurence S
authors.initials: LS
authors.lastname: Lim
authors.affiliation: Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.
authors.forename: Chui Ming Gemmy
authors.initials: CMG
authors.lastname: Cheung
authors.affiliation: Centre for Vision Research, University of Sydney, Sydney, Australia.
authors.forename: Paul
authors.initials: P
authors.lastname: Mitchell
authors.affiliation: Singapore Eye Research Institute, Singapore National Eye Centre, Singapore; Department of Ophthalmology, National University of Singapore, Singapore. Electronic address: ophwty@nus.edu.sg.
authors.forename: Tien Y
authors.initials: TY
authors.lastname: Wong
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000188:drug therapy; D006801:Humans; D007231:Infant, Newborn; D008268:Macular Degeneration / Q000188:drug therapy; D009885:Ophthalmology / Q000592:standards; D017410:Practice Guidelines as Topic; D000069579:Ranibizumab; D012170:Retinal Vein Occlusion / Q000188:drug therapy; D012178:Retinopathy of Prematurity / Q000188:drug therapy; D013810:Therapeutic Equivalency; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab